All In Biotech

Drug Trial Radar · NCT01526785

A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease

A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale

Last checked: Nov 20, 2026Latest source record: Dec 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

113

Actual

Start

Mar 2012

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Feb 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study was to evaluate the efficacy and safety of treatment with 4000 litre (L) alglucosidase alfa (Lumizyme®) in Pompe participants.

Conditions

  • Pompe Disease

Interventions

  • Alglucosidase alfaDrug

    4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Were Clinically Stable or Improved at Week 52Time frame: Week 52

Locations

51 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Oakland, California

  • Site not named

    Orange, California

  • Site not named

    San Diego, California

  • Site not named

    San Jose, California

  • Site not named

    Stanford, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Gainesville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Decatur, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Kansas City, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Jackson, Mississippi

  • Site not named

    Columbia, Missouri

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    New Brunswick, New Jersey

  • Site not named

    Glens Falls, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Syracuse, New York

  • Site not named

    Valhalla, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Philadelphia, Pennsylvania

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.